Though inflammatory bowel disease patients are generally at higher risk of HPV-related cancers, this data did not support intensified screening for vulvar or vaginal malignancies in female IBD patients.
Copper intrauterine device users were found to have a lower risk of high-grade cervical neoplasms compared with levonorgestrel-releasing intrauterine system users.
These findings indicate that bone mineral density screening and pharmacologic intervention should be strongly considered for these high-risk women.
The FDA granted fast track designation to balstilimab and zalifrelimab based on comprehensive data found to support their potential as a combination therapy.
The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab.
This study suggested that the National Comprehensive Cancer Network Distress Thermometer problem list does not easily identify concerns most associated with high distress and low quality of life in women with gynecologic cancers.
These results could present an opportunity to broaden inclusion criteria on clinical trials and intensify chemoradiotherapy treatments.
Niraparib was approved by the (FDA) for previously treated advanced ovarian, fallopian, or primary peritoneal cancers.
COX7RP contributes to endometrial and breast cancer growth.
Diagnosis of endometrial carcinoma made easier by analysis of mutations in cervix or endometrial tissue.